Stock Events

Stock Events

Clene 

$4.47
48
-$0.18-3.87% Thursday 20:00
+$0.00+0%Thursday 20:10After hours

Statistics

Day High
4.47
Day Low
4.47
52W High
13.5
52W Low
3.88
Volume
300
Avg. Volume
-
Mkt Cap
57.43M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.33
-0.92
-0.5
-0.09
Expected EPS
-0.454
Actual EPS
N/A

Financials

-13,086.5%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
200,000Revenue
-26.17MNet Income

Analyst Ratings

34.00Average Price Target
The highest estimate is 48.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CLNN. It's not an investment recommendation.
NVIDIA
10
NVDA
Apple
9
AAPL
Microsoft
8
MSFT
Tesla
8
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap32.03B
Biogen focuses on neurodegenerative diseases, directly competing with Clene's CNS disorder treatments.
AnaptysBio
ANAB
Mkt Cap1.71B
AnaptysBio works on developing novel therapeutics for inflammation, competing in the broader scope of Clene's target markets.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.61B
Alnylam Pharmaceuticals specializes in RNAi therapeutics for genetic diseases, including neurological disorders.
Ionis Pharmaceuticals
IONS
Mkt Cap9.93B
Ionis Pharmaceuticals focuses on RNA-targeted drug discovery, including treatments for neurological diseases.
PTC Therapeutics
PTCT
Mkt Cap5.83B
PTC Therapeutics offers treatments for rare disorders, including CNS diseases, competing with Clene's therapeutic areas.
Akebia Therapeutics
AKBA
Mkt Cap251.22M
Akebia Therapeutics, though focused on kidney disease, competes for similar investment and research resources.
Vertex Pharmaceuticals
VRTX
Mkt Cap138.91B
Vertex Pharmaceuticals, with a broad pipeline including pain management, indirectly competes in the neurological space.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.87B
Regeneron Pharmaceuticals, known for its innovative biologics, competes in the broader biotech space for resources and investment.
Novartis
NVS
Mkt Cap301.95B
Novartis offers a wide range of healthcare solutions, including treatments for neurological conditions, competing on a global scale.

About

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
Show more...
CEO
Robert Etherington
Employees
79
Country
United States
ISIN
US1856342019
WKN
000A40G3Z

Listings

BOATS
BOATS
CLNN.BOATS
F
DE
84C0.F
XNAS
US
CLNN

0 Comments

Share your thoughts

FAQ

What is Clene stock price today?▼
The current price of CLNN is $4.47 USD — it has decreased by -3.87% in the past 24 hours. Watch Clene stock price performance more closely on the chart.
What is Clene stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Clene stocks are traded under the ticker CLNN.
Is Clene stock price growing?▼
CLNN stock has risen by +3.47% compared to the previous week, the month change is a -10.42% fall, over the last year Clene has showed a -17.38% decrease.
What is Clene market cap?▼
Today Clene has the market capitalization of 57.43M
When is the next Clene earnings date?▼
Clene is going to release the next earnings report on November 10, 2026.
What were Clene earnings last quarter?▼
CLNN earnings for the last quarter are -1.08 USD per share, whereas the estimation was -0.37 USD resulting in a -193.48% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Clene revenue for the last year?▼
Clene revenue for the last year amounts to 200,000 USD.
What is Clene net income for the last year?▼
CLNN net income for the last year is -26.17M USD.
How many employees does Clene have?▼
As of August 28, 2026, the company has 79 employees.
In which sector is Clene located?▼
Clene operates in the Health & Wellness sector.
When did Clene complete a stock split?▼
The last stock split for Clene was on July 11, 2024 with a ratio of 1:20.
Where is Clene headquartered?▼
Clene is headquartered in SALT LAKE CITY, United States.